{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:18Z","timestamp":1787841318815,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>The neoadjuvant chemotherapy in HER2-positive breast cancer consists of a chemotherapy backbone and HER2-directed therapy. The increase in cardiotoxicity by the use of trastuzumab with an anthracycline-based regimen has led to the use of nonanthracycline-based alternative regimens. The docetaxel, carboplatin, and trastuzumab (TCH) are one such regimen. The efficacy and toxicity of this regimen have not been widely studied in Indian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIMS:<\/jats:title>\n                    <jats:p>This retrospective study aims to evaluate the efficacy and toxicity of neoadjuvant TCH regimen in locally advanced and oligometastatic HER2-positive breast cancer in Indian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODOLOGY:<\/jats:title>\n                    <jats:p>\n                      The hospital records between January 2014 and December 2016 were reviewed to identify patients with locally advanced and oligometastatic HER2-positive breast cancer treated with uniform 3-weekly neoadjuvant chemotherapy protocol-containing docetaxel (75 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), carboplatin (AUC = 6), and trastuzumab (8 mg\/kg loading followed by 6 mg\/kg) (TCH). The primary outcome was the pathologic complete response (pCR), which was defined as an absence of invasive and noninvasive cancer in breast or lymphnode.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Thirty-two patients with mean age 46 years met our inclusion criteria, of these 24 patients had locally advanced breast cancer, and eight patients had oligometastatic breast cancer. 13 (40.6%) patients had hormone-positive breast cancer. The objective response rate as assessed clinically was 100%, and pCR rate was 36.3%. The patients with oligometastatic breast cancer also showed a good response to chemotherapy with three patients showing pCR and four patients showing resolution disease at metastatic sites. The patients experienced very few Grade III\/IV toxicities, and no patient had clinical congestive heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The TCH protocol is an efficacious neoadjuvant chemotherapy regimen for locally advanced and oligometastatic breast cancer and is safe and well tolerated in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_152_17","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:43:22Z","timestamp":1513817002000},"page":"343-346","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience"],"prefix":"10.4103","volume":"54","author":[{"given":"A","family":"Tiwari","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gogia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SVS","family":"Deo","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NK","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mathur","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DN","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"R1-20250920","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.7314\/APJCP.2014.15.5.1989","article-title":"Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: Institutional experience","volume":"15","author":"Gogia","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R2-20250920","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"R3-20250920","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"R4-20250920","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"key":"R5-20250920","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20250920","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"Pegram","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R7-20250920","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","article-title":"Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers","volume":"18","author":"Pegram","year":"1999","journal-title":"Oncogene"},{"key":"R8-20250920","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-20250920","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clbc.2016.06.010","article-title":"Anthracycline-free neoadjuvant chemotherapy ensures higher rates of pathologic complete response in breast cancer","volume":"17","author":"De Iuliis","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"R10-20250920","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3892\/ol.2015.2912","article-title":"Efficacy of TCH\/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer","volume":"9","author":"Chen","year":"2015","journal-title":"Oncol Lett"},{"key":"R11-20250920","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-016-4098-z","article-title":"Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer","volume":"162","author":"Echavarria","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"R12-20250920","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2006.09.9994","article-title":"Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN(A)-1 trial","volume":"25","author":"Coudert","year":"2007","journal-title":"J Clin Oncol"},{"key":"R13-20250920","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000452079","article-title":"Neoadjuvant chemotherapy with docetaxel, carboplatin and weekly trastuzumab is active in HER2-positive early breast cancer: Results after a median follow-up of over 4 years","volume":"11","author":"Kolberg","year":"2016","journal-title":"Breast Care (Basel)"},{"key":"R14-20250920","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-016-3866-0","article-title":"Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab\/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer","volume":"158","author":"Tiwari","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R15-20250920","first-page":"CD005002","article-title":"Preoperative chemotherapy for women with operable breast cancer","volume":"2","author":"Mieog","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20250920","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R17-20250920","first-page":"190","article-title":"Association between efficacy and molecular subtypes in breast cancer patients receiving neoadjuvant chemotherapy","volume":"38","author":"Niu","year":"2016","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R18-20250920","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J Clin Oncol"},{"key":"R19-20250920","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"Loibl","year":"2014","journal-title":"J Clin Oncol"},{"key":"R20-20250920","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223310-201754010-00070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:39Z","timestamp":1787838579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223310-201754010-00070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_152_17","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}